No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATRC240719C20000
- 3.89
- -2.11-35.17%
15min DelayClose Jul 19 15:58 ET
3.89High3.89Low
3.89Open6.00Pre Close4 Volume908 Open Interest20.00Strike Price1.56KTurnover1252.00%IV-1.16%PremiumJul 19, 2024Expiry Date4.17Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9416Delta0.0383Gamma5.69Leverage Ratio-4.6499Theta0.0000Rho5.36Eff Leverage0.0003Vega
Intraday
- 5D
- Daily
News
AtriCure, Inc. (NASDAQ:ATRC) Might Not Be As Mispriced As It Looks
There wouldn't be many who think AtriCure, Inc.'s (NASDAQ:ATRC) price-to-sales (or "P/S") ratio of 2.8x is worth a mention when the median P/S for the Medical Equipment industry in the United States
AtriCure to Announce Second Quarter 2024 Financial Results
AtriCure, Inc. ((
Analyst Ratings For AtriCure
AtriCure (NASDAQ:ATRC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below summarizes their recent ratings, show
AtriCure Price Target Maintained With a $40.00/Share by Needham
AtriCure Price Target Maintained With a $40.00/Share by Needham
Express News | Needham Reiterates Buy on AtriCure, Maintains $40 Price Target
AtriCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 78.17% Needham $40 → $40 Reiterates Buy → Buy 05/02/2024 118.26% Canaccord Genuity $57 → $49 Ma
Comments
Insider transactions at AtriCure are not encouraging. However, insiders' share ownership suggests some alignment. Maggie Yuen's sale at a price above the current share price may not reflect insider confidence.
Investors forecast sustained strong revenue performance from AtriCure, reflected in a high P/S ratio. Shareholders currently show confidence in the company's future revenue, bolstering its shares. The high P/S ratio is deemed appropriate due to robust future revenues.
The lack of insider purchasing and ample selling in the past year could be red flags for potential investors in AtriCure. Despite high insider ownership, absence of buying is unsettling. Additionally, unspecified risks and concerns for AtriCure are noteworthy.
Read more